About Kynexis
Kynexis is a company based in Cambridge (United States) founded in 2023.. Kynexis has raised $61.19 million across 1 funding round from investors including Forbion, Ysios Capital and Sunstone. Kynexis offers products and services including KYN-5356. Kynexis operates in a competitive market with competitors including Noema Pharma, Neurosterix, LB Pharmaceuticals and Huili Pharmaceutical, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$61.19 M (USD)
in 1 rounds
-
Latest Funding Round
$61.19 M (USD), Series A
Nov 07, 2023
-
Investors
Forbion
& 2 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kynexis
Kynexis offers a comprehensive portfolio of products and services, including KYN-5356. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhibits KAT-II enzyme to address cognitive impairment in schizophrenia patients.
Unlock access to complete
Unlock access to complete
Funding Insights of Kynexis
Kynexis has successfully raised a total of $61.19M through 1 strategic funding round. The most recent funding activity was a Series A round of $61.19 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $61.2M
-
First Round
First Round
(07 Nov 2023)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2023 | Amount | Series A - Kynexis | Valuation | Forbion |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Kynexis
Kynexis has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Forbion, Ysios Capital and Sunstone. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on lifescience and healthcare sectors
|
Founded Year | Domain | Location | |
|
Ysios Capital is recognized as a leading life sciences investor.
|
Founded Year | Domain | Location | |
|
Investments are made by Sunstone in early-stage European companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Kynexis
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Kynexis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Kynexis Comparisons
Competitors of Kynexis
Kynexis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Noema Pharma, Neurosterix, LB Pharmaceuticals and Huili Pharmaceutical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutic solutions for neurological disorders treatment are developed.
|
|
| domain | founded_year | HQ Location |
Allosteric modulators for neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for schizophrenia are developed.
|
|
| domain | founded_year | HQ Location |
Peptide drugs and microsphere preparations for neurological disorders are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Kynexis
When was Kynexis founded?
Kynexis was founded in 2023.
Where is Kynexis located?
Kynexis is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Kynexis?
Kees Been is the current CEO of Kynexis.
Is Kynexis a funded company?
Kynexis is a funded company, having raised a total of $61.19M across 1 funding round to date. The company's 1st funding round was a Series A of $61.19M, raised on Nov 07, 2023.
What does Kynexis do?
Developer of precision treatments for cognitive impairment associated with schizophrenia. it offers biomarker-based test to identify therapies for patients which include KYN-5356 a first-in-class small molecule that is a potent and selective KAT-II inhibitor a key enzyme in the kynurenine pathway for the treatment of schizophrenia.
Who are the top competitors of Kynexis?
Kynexis's top competitors include Noema Pharma, LB Pharmaceuticals and Neurosterix.
What products or services does Kynexis offer?
Kynexis offers KYN-5356.
Who are Kynexis's investors?
Kynexis has 3 investors. Key investors include Forbion, Ysios Capital, and Sunstone.